TABLE 2.
Signaling Pathways That Interfere With GBC-specific Sensitivity to Chemotherapeutics
| Pathway | Cell lines | Drugs | Research types | Event | Sensitivity to drugs (in vitro) | Year |
|---|---|---|---|---|---|---|
| p38 | SGC996+GBC-SD | CDDP+5-FU42 | vtr | — Inhibit | — Down | 2018 |
| HIF1α/MDR1 | GBC-SD+SGC-996 | CDDP30 | vtr | — Activate | — Down | 2015 |
| PI3K/Akt | GBC-SD+NOZ | GEM17 | vtr | — Inhibit | — Up | 2021 |
| NF-κB/β-catenin | G-415 | GEM29 | vtr | — Inhibit | — Up | 2020 |
| Hedgehog | TYGBK-1+NOZ+TGBC2TKB | GEM28 | vtr | — Inhibit | — Down | 2021 |
| MEK/ERK+PI3K—AKT | GBC-SD+SGC-996 | 5-FU77 | vtr | — Inhibit | — Up | 2020 |
| Mitochondrial-Dependent Apoptosis Pathway | GBC-SD | Epirubicin78 | vtr | — Inhibit | — Down | 2011 |
| NF-κB | GBC-SD+EH-GB1+EH-GB2 | GEM79 | vtr | — Inhibit | — Up | 2015 |
| Hippo-YAP1 | GBC-PDOs | GEM80 | vtr | — Inhibit | — Up | 2020 |
| EGFR/HER2 | TGBC1-TKB | GEM81 | vtr | — Inhibit | — Up | 2010 |
5-FU indicates 5-fluorouracil; CDDP, cisplatin; cli, clinical research; Dox, doxorubicin; DTX, docetaxel; GBC, gallbladder cancer; GEM, gemcitabine; KD, knockdown; KO, knockout; OE, overexpress; OXA, oxaliplatin; vtr, in vitro; vvo, in vivo.